Table 5 Five year cumulative incidence of cancer and competitive mortality
Covariate | Cancer events | Competitive mortality | ||||
|---|---|---|---|---|---|---|
Cumulative Incidence | 95% CI | p | Cumulative Incidence | 95% CI | p | |
Sex | ||||||
Male | 40.4 | 34.0–46.7 | 0.3 | 11.0 | 7.7–16.0 | 0.48 |
Female | 33.3 | 13.6–54.6 | 14.0 | 4.3–29.2 | ||
Comorbidity | ||||||
0–1 | 35.50 | 29.2–41.8 | 0.29 | 7.0 | 4.6–11.7 | 0.01 |
2–6 | 33.30 | 20.7–46.4 | 24.6 | 17.9–46.2 | ||
ECOG | ||||||
0 | 30.20 | 23.2–37.4 | 0.01 | 9.30 | 5.5–14.6 | 0.35 |
1–2 | 42.30 | 33.0–51.3 | 11.0 | 6.2–17.5 | ||
Stage | ||||||
III | 24.4 | 16.6–33.1 | 0.01 | 11.7 | 6.4–18.9 | 0.21 |
IV | 41.8 | 34.1–49.1 | 9.0 | 5.4–13.9 | ||
Location | ||||||
Oral Cavity | 41.0 | 17.8–63.5 | 0.35 | 10.0 | 2.5–23.9 | 0.99 |
Oropharynx | 39.0 | 27.8–49.8 | 13.0 | 6.6–21.9 | ||
Larynx | 37.0 | 28.2–45.5 | 11.0 | 6.3–17.4 | ||
Hypopharynx | 52.0 | 32.6–68.6 | 10.0 | 3.2–22.2 | ||
Treatment | ||||||
ICT | 52.00 | 36.3–65.6 | 0.01 | 3.92 | 0.7–12.0 | 0.63 |
CRT | 27.10 | 20.3–34.3 | 10.1 | 6.6–16.6 | ||
RTCTX | 41.60 | 30.0–52.7 | 12.4 | 6.0–21.1 | ||
RT Technique | ||||||
3DRT | 40.0 | 33.0–46.4 | 0.8 | 12.5 | 8.4–17.4 | 0.4 |
IMRT | 58.0 | 17.9–84.0 | 8.0 | 2.7–17.8 | ||
RT Fractionation | ||||||
Conventional | 37.0 | 29.1–45.4 | 0.63 | 12.0 | 7.2–17.8 | 0.66 |
Others | 43.0 | 33.7–52.5 | 12.0 | 6.5–18.6 | ||
Acute PL toxicity | ||||||
0–1 | 28.1 | 15.9–41.6 | 0.5 | 9.0 | 2.7–19.3 | 0.34 |
≥ 2 | 36.6 | 30.2–42.8 | 10.3 | 6.8–14.7 | ||
Acute mucosa toxicity | ||||||
0–2 | 36.4 | 28.6–44.2 | 0.66 | 7.4 | 3.9–12.5 | 0.07 |
3–5 | 34.0 | 25.8–42.3 | 13.0 | 7.9–19.5 | ||
Chronic PL toxicity | ||||||
0–1 | 35.8 | 32.6–47.5 | 0.93 | 11.3 | 8.3–18.2 | 0.47 |
≥ 2 | 34.1 | 27.8–49.5 | 8.0 | 3.5–15.3 | ||